Results for the substance live, attenuated tetravalent dengue vaccine

The live attenuated tetravalent dengue vaccine is used to prevent dengue fever, a viral disease transmitted by the bite of Aedes mosquitoes. The vaccine contains attenuated forms of the four dengue virus serotypes, which stimulate the immune system to produce antibodies against them, providing protection against infection.

The vaccine is administered subcutaneously, usually in three doses, at six-month intervals. It is recommended for individuals aged 9 to 45 years who live in endemic areas and have had a prior confirmed dengue virus infection.

Common side effects include pain at the injection site, fever, headache, and fatigue. In rare cases, severe adverse reactions such as allergic reactions or complications associated with secondary dengue infection may occur.

The live attenuated tetravalent dengue vaccine is an important measure for reducing the incidence and severity of dengue fever in endemic regions, helping to protect at-risk populations.